Publications

Publications

337 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

GVS assessment of calcifediol (Hidroferol®)

Zorginstituut Nederland has completed its assessment whether calcifediol (Hidroferol®) is interchangeable with a medicine already ...

Report | 01-07-2021

Package advice niraparib (Zejula®)

Zorginstituut Nederland has completed its assessment whether niraparib (Zejula®) can be included in the insured package. ...

Report | 24-06-2021

GVS advice SGLT-2 inhibitors

Zorginstituut Nederland has completed its assessment the further conditions of SGLT-2 inhibitors canagliflozin (Invokana®), ...

Report | 22-06-2021

GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia

Zorginstituut Nederland has completed its assessment whether the recombinant herpes zoster vaccine with adjuvant (RZV, Shingrix®) ...

Report | 14-06-2021

GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia

Zorginstituut Nederland has completed its assessment whether avatrombopag (Doptelet®) is interchangeable with a product that is ...

Report | 08-06-2021

GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection

Zorginstituut Nederland has completed its assessment whether the products Rekambys® and Vocabria® can be included in the ...

Report | 08-06-2021

Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma

Zorginstituut Nederland has completed its assessment whether isatuximab (Sarclisa®) in combination with carfilzomib and ...

Report | 25-05-2021

GVS advice ivacaftor (Kalydeco®) extension of further conditions

Zorginstituut Nederland carried out a review to extend the further conditions for reimbursement of ivacaftor (Kalydeco®). The ...

Report | 25-05-2021

GVS advice dapagliflozin (Forxiga®) extension of further condition

Zorginstituut Nederland has completed its assessment whether the further condition of dapagliflozin (Forxiga®) could be extended. ...

Report | 12-05-2021

Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer

Zorginstituut Nederland has completed its assessment whether the fixed combined dose of pertuzumab and trastuzumab (Phesgo®) can ...

Report | 11-05-2021